NBIX$146.100.19%-0.28
After Hours: 143.00-3.10 -2.12%
Neurocrine Biosciences Inc (NBIX)
Date: 2026-10-30 16:00O: 147.13H: 149.25L: 145.22C: 146.10Vol: 1.321M
Neurocrine Biosciences Inc stock is traded at $146.10, with a volume of 1,321,060. It is down -0.19% in the last 24 hours and up +3.00% over the past month. Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
Previous Close:
$146.38
Open:
$147.13
24h Volume:
1,321,060
Relative Volume:
1.19
Market Cap:
$14.85B
Revenue:
$3.10B
Net Income/Loss:
$668.60M
P/E Ratio:
22.46
EPS:
$6.50
Net Cash Flow:
$831.30M
1W Performance:
+2.38%
1M Performance:
+3.00%
6M Performance:
+10.96%
1Y Performance:
+5.84%
1-Day Range:
$145.22$149.25
1-Week Range:
$142.34$149.25
52-Week Range:
$122.14$186.12
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
Name
Neurocrine Biosciences IncSector
HealthcarePhone
(858) 617-7600Address
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA, USACompare NBIX vs TAK, TEVA, HLN, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NBIX Neurocrine Biosciences Inc | $146.10 | $14.85B | $3.10B | $668.60M | $831.30M | $6.50 |
 TAK Takeda Pharmaceutical Co Adr | $20.91 | $66.81B | $29.91B | $1.30B | $3.49B | $0.4056 |
 TEVA Teva Pharmaceutical Industries Ltd Adr | $42.09 | $49.09B | $17.53B | $1.58B | $444.18M | $1.35 |
 HLN Haleon Plc Adr | $8.66 | $38.08B | $14.54B | $2.22B | $2.58B | $0.4871 |
 ZTS Zoetis Inc | $79.72 | $32.94B | $9.51B | $2.64B | $2.14B | $6.04 |
 UTHR United Therapeutics Corp | $598.72 | $25.68B | $3.17B | $1.29B | $1.01B | $27.09 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
Neurocrine Biosciences Inc Stock (NBIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Neurocrine Biosciences Inc Stock (NBIX) Insider Trading
- Boyer David W.Sep 14 '26Chief Corp. Affairs Officer
- Transaction
- Sale
- Cost
- $157.45
- #Shares
- 826
- Value ($)
- 130,051
- #Shares Total
- 8,722
- DAVID WARREN BOYERSep 14 '26Officer
- Transaction
- Proposed Sale
- Cost
- $156.22
- #Shares
- 4,714
- Value ($)
- 736,421
- #Shares Total
- 0
- MATTHEW C ABERNETHYSep 14 '26Officer
- Transaction
- Proposed Sale
- Cost
- $156.22
- #Shares
- 2,311
- Value ($)
- 361,024
- #Shares Total
- 0
- ABERNETHY MATTSep 14 '26Chief Financial Officer
- Transaction
- Sale
- Cost
- $157.20
- #Shares
- 2,311
- Value ($)
- 363,285
- #Shares Total
- 42,808
- BENEVICH ERICSep 09 '26Chief Commercial Officer
- Transaction
- Option Exercise
- Cost
- $43.24
- #Shares
- 3,194
- Value ($)
- 138,109
- #Shares Total
- 66,562
- BENEVICH ERICSep 09 '26Chief Commercial Officer
- Transaction
- Sale
- Cost
- $154.61
- #Shares
- 2,154
- Value ($)
- 333,030
- #Shares Total
- 64,408
- ERIC BENEVICHSep 09 '26Officer
- Transaction
- Proposed Sale
- Cost
- $155.13
- #Shares
- 2,154
- Value ($)
- 334,150
- #Shares Total
- 0
- Norwalk Leslie VJul 29 '26Director
- Transaction
- Option Exercise
- Cost
- $139.43
- #Shares
- 842
- Value ($)
- 117,400
- #Shares Total
- 2,430
- Norwalk Leslie VJul 28 '26Director
- Transaction
- Sale
- Cost
- $182.01
- #Shares
- 1,250
- Value ($)
- 227,508
- #Shares Total
- 1,588
- INGRID DELAETJul 10 '26Officer
- Transaction
- Proposed Sale
- Cost
- $180.55
- #Shares
- 4,367
- Value ($)
- 788,462
- #Shares Total
- 0
